Regulus Therapeutics reported $155K in Interest Expense on Debt for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Interest Expense On Debt Change
Alnylam Pharmaceuticals ALNY:US $ 42.36M 5.55M
Biogen BIIB:US $ 66.1M 0.2M
Gilead Sciences GILD:US $ 238M 0M
Intercept Pharmaceuticals ICPT:US $ 6.67M 8.64M
Intrexon XON:US $ 2.07M 2.82M
IONIS PHARMACEUT IONS:US $ 2.12M 0.12M
Lexicon Pharmaceuticals LXRX:US 110K 185K
Ligand Pharmaceuticals LGND:US $ 0.79M 3.68M
Merk MRK:US $ 243M 34M
Omeros OMER:US $ 4.94M 10K
Regulus Therapeutics RGLS:US $ 0.16M 0.06M
YTE INCY:US $ 0.68M 0.07M